Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039390 · ClinicalTrials.gov registry record · Phase 1
Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT00039390: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00039390 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 41 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00039390, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of gefitinib and capecitabine in treating patients with advanced solid tumors. Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining gefitinib and capecitabine may kill more tumor cells
Interventions
- OTHER laboratory biomarker analysis
- DRUG capecitabine
- OTHER pharmacological study
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2002-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00039390
The ClinicalTrials.gov registry entry for NCT00039390 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00039390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00039390 about?
NCT00039390 is a clinical study titled "Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors". This phase I trial is studying the side effects and best dose of gefitinib and capecitabine in treating patients with advanced solid tumors. Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of solid tumors. Drugs used in chemotherapy use differe...
What is the current status of trial NCT00039390?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2002-04.
What interventions are being tested in trial NCT00039390?
The interventions under investigation include: laboratory biomarker analysis (OTHER), capecitabine (DRUG), pharmacological study (OTHER), gefitinib (DRUG).
Who is sponsoring clinical trial NCT00039390?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.